About: Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2 Nucleocapsid Phosphoprotein RNA Binding Domain: In silico analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2 Nucleocapsid Phosphoprotein RNA Binding Domain: In silico analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2 Nucleocapsid Phosphoprotein RNA Binding Domain: In silico analysis
Creator	Chukwudozie, Onyeka Chukwuanukwu, Rebecca Daniel, Eze Kehinde, Busuyi Onaopemipo, Dele-Alimi Onyekachi, Iroanya Perpetua, Obi Taiwo, Bankole Vincent, Duru
Source	BioRxiv
abstract	The novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has previously never been identified with humans, thereby creating devastation in public health. The need for an effective vaccine to curb this pandemic cannot be overemphasized. In view of this, we, therefore, designed a subcomponent antigenic peptide vaccine targeting the N-terminal (NT) and C-terminal (CT) RNA binding domains of nucleocapsid protein that aid in viral replication. Promising antigenic B-cells and T cell epitopes were predicted using computational pipelines. The peptides “RIRGGDGKMKDL” and “AFGRRGPEQTQGNFG” were the B cell linear epitopes with good antigenic index and non-allergenic property. Two CD8+ and Three CD4+ T-cell epitopes were also selected considering their safe immunogenic profiling such as allergenicity, antigen level conservancy, antigenicity, peptide toxicity, and putative restrictions to a number of MHC-I and II alleles. With these selected epitopes, a non-allergenic chimeric peptide vaccine incapable of inducing a Type II hypersensitivity reaction was constructed. The molecular interaction between the toll-like receptor-5 (TLR5) which was triggered by the vaccine was analyzed by molecular docking and scrutinized using dynamics simulation. Finally, in silico cloning was performed to ensure the expression and translation efficiency of the vaccine, utilizing pET-28a vector. This research, therefore, provides a guide for experimental investigation and validation.
has issue date	2020-07-01(xsd:dateTime)
bibo:doi	10.1101/2020.06.30.176537
has license	biorxiv
sha1sum (hex)	40287d235b556cb45b5bc6cc0ad773a55bc74184
schema:url	https://doi.org/10.1101/2020.06.30.176537
resource representing a document's title	Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2 Nucleocapsid Phosphoprotein RNA Binding Domain: In silico analysis
schema:publication	bioRxiv
resource representing a document's body	covid:40287d235b556cb45b5bc6cc0ad773a55bc74184#body_text
is schema:about of	named entity 'translation' named entity 'protein' named entity 'toll-like receptor' named entity 'public health' named entity 'With' named entity 'dynamics simulation' named entity 'vaccine' named entity 'reaction' named entity 'investigation' named entity 'antigenic' named entity 'RNA' named entity 'In silico' named entity 'Domain' named entity 'DYNAMICS SIMULATION' named entity 'T CELL' named entity 'PET' named entity 'ANTIGENICITY' named entity 'VACCINE' named entity 'NOVEL CORONAVIRUS' named entity 'cloning' named entity 'pandemic' named entity 'Type II hypersensitivity' named entity 'molecular interaction' named entity 'N-terminal' named entity 'peptides' named entity 'conservancy' named entity 'toxicity' named entity 'MHC-I' named entity 'inducing' named entity 'epitopes' named entity 'vaccine' named entity 'toll-like receptor' named entity 'antigenicity' named entity 'peptides' named entity 'Type II hypersensitivity' named entity 'CD8 +' named entity 'public health' named entity 'immunogenic' named entity 'antigenic' named entity 'TLR5' named entity 'peptide' named entity 'antigenic' named entity 'vector' named entity 'viral replication' named entity 'peptide vaccine' named entity 'N-terminal' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'SARS-CoV-2' named entity 'protein structure' named entity 'epitopes' named entity 'protein sequence' named entity 'NCBI' named entity 'Pymol' named entity 'antibody' named entity 'conserved regions' named entity 'proteases' named entity 'epitope' named entity 'severe acute respiratory syndrome coronavirus' named entity 'nucleocapsid protein' named entity 'structural alignment' named entity '1, 2' named entity 'protein' named entity 'functional analogs' named entity 'nucleocapsid' named entity 'I-TASSER' named entity 'helical' named entity 'W53' named entity '3D structure' named entity 'cellular immune' named entity 'I-TASSER' named entity 'China' named entity 'peptides' named entity 'hydrophilic' named entity 'antigens presented' named entity 'Coronaviruses' named entity 'lymphocytes'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software